About 13 results found for searched term "PD-1/PD-L1" (0.036 seconds)
|M5144||BMS202||Bms-202 is an effective non-peptide PD-1/PD-L complex inhibitor with IC50 of 18 nM and KD of 8 μM. Bms-202 directly binds to PD-L1 and blocks the human PD-1/PD-L interaction. Bms-202 has antitumor activity.|
|M8959||BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1)||BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) is an inhibitor of PD-1/PD-L1 protein/protein interaction with an IC50 of 6 to 100 nM.|
|M10290||BMS-1166||BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor, which binds to human PD-L1 and blocks its interaction with PD-1.|
|M11354||INCB086550||INCB086550 selectively inhibited PD-L1 with IC50 of 3.1 nM, 4.9 nM and 1.9 nM for human, rhesus monkey and rat pD-L1, respectively. INCB086550 could not inhibit the binding of PD-L2 to PD-1 at 10 μM. INCB086550 significantly inhibits the PD-1/PD-L1 signaling axis by binding to PD-L1 protein, leading to PD-L1 dimerization and internalization, and has good tumor suppressive effect in a variety of mouse tumor models.|
|M11456||Evixapodlin||Evixapodlin (PD-1/ PD-L1-in 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. Evixapodlin has anti-cancer and anti-virus properties.|
|M21327||Human PD-L1 inhibitor V||Human PD-L1 inhibitor V is a human PD-1 protein binding peptide with a Kd value of 3.32 μM that inhibits the binding of human PD-1/PD-L1.Sequence:Leu-Asp-Tyr-Val-Asn-Arg-Arg-Lys-Met-Tyr-Gln.|
|M24808||Camrelizumab||Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al.|
|M24961||PD-1/PD-L1-IN-20||PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC50 of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases.|
|M25029||Tebotelimab||Tebotelimab (MGD-013) is a human IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity.|
|M25031||Adebrelimab||Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC).|
|M25050||Acasunlimab||Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer.|
|M25343||Sudubrilimab||Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment.|
|M25528||(D) PPA-1 TFA||(D) PPA-1 TFA is the first hydrolysisresistant D-peptide antagonists to target the PD-1/PD-L1 pathway. (D) PPA-1 could bind PD-L1 at an affinity of 0.51 μM in vitro.|
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.